Martin Center Sickle Cell Initiative (MCSCI) and the Indiana Hemophilia and Thrombosis Center (IHTC) will present the 2015 Indiana Sickle Cell Conference on April 24, 2015. The conference will take place at the Ivy Tech Community College Corporate College and Culinary Center at 2820 N. Meridian Street. It will begin with registration and a continental breakfast at 8:00 A.M. and will conclude at 4:30 P.M. The conference theme, “Empowering our Future,” was chosen to highlight the need to empower physicians and patients as they battle Sickle Cell from their respective positions.
The conference will include both a medical track for health care providers and a community track for SCD patients and their families, social service providers and advocates. Continuing medical education credits will be available. Sonja Banks, the President and COO of the Sickle Cell Disease Association of America will be the keynote speaker. Banks will be joined by local physicians, as well as from around the nation, to discuss clinical aspects of the disease. Among the nationally known physicians joining the program are Dr. Kim Smith-Whitely of the Children’s Hospital of Philadelphia, Dr. Russell Ware of Cincinnatti Children’s Hospital and Dr. Alexis Thompson of the Ann & Robert H. Lurie Children’s Hospital of Chicago.
The objectives of the conference are:
- To alert the Indiana community about the continued presence of SCD and to inform the community about the many lesser known varieties of pain (psychological, emotional, social, economic and spiritual) that accompany the physical pain associated with SCD.
- To empower health care providers by providing up-to-date recommended treatment protocols for SCD.
- To empower those who have SCD by providing information that allows them to better care for themselves.
Friends of MCSCI know that it is the only agency of its kind in the state of Indiana. It exists to aid and enhance the lives of those affected by Sickle Cell and associated disorders by providing supportive services, education and advocacy. The Indiana Hemophilia and Thrombosis Center is committed to providing the highest quality comprehensive healthcare services to patients with bleeding and clotting disorders, and to their families. The agencies have worked together for several years but this is the first time that they have co-presented this important conference. The conference is being sponsored in part by Mast Therapeutics, a publicly traded biopharmaceutical company headquartered in San Diego, California. Mast has developed a pharmaceutical agent called MST-188 and is enrolling Sickle Cell Disease patients in a phase 3 clinical trial study known as EPIC.